MedPath

A study comparing two different anti vomiting drugs in preventing injection pain of anesthesia inducing drug

Completed
Conditions
Laproscopic surgeries
Registration Number
CTRI/2018/01/011293
Lead Sponsor
Shamshuzoha M
Brief Summary

Intravenous Propofol causes pain on injection, different drugs have been used to prevent Propofol injection pain 5HT3 receptor antagonist which are commonly used for prevention of nausea and vomiting are also used for having analgesic property. Different 5HT3 receptor antagonists were used as pretreatment in preventing this pain. In literature there are very minimal studies comparing Ondensetron and Palonosetron as pretreatment in preventing the Propofol injection pain.

The overall incidence of pain in group Ondensetron and group Palonosetron was 32% and 26% respectively. 4% of patient in group Ondensetron and 2% of patient in group Palonosetron complained of severe pain. Incidence of post operative nausea and vomiting in group Palonosetron (20%) was comparatively lower than group Ondensetron (38%).

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
100
Inclusion Criteria

Posted for elective Laproscopic surgery under General anesthesia.

Exclusion Criteria

Patients with presence of infection on the dorsum of non-dominant hand Patients with thin dorsal veins Patients with known hypersensitivity to Propofol, Ondensetron and Palonosetron.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pain during injection of Propofol1, 3 and 5 minute after induction
Secondary Outcome Measures
NameTimeMethod
Post operative nausea and vomitingNoted for 24 hours Post operative period

Trial Locations

Locations (1)

Kempegowda Institute of Medical Sciences

🇮🇳

Bangalore, KARNATAKA, India

Kempegowda Institute of Medical Sciences
🇮🇳Bangalore, KARNATAKA, India
Shamshuzoha M
Principal investigator
9742131215
shamshuzoha@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.